je.st
news
Tag: asco
Positive clinical data of CytRx's aldoxorubicin to be presented at ASCO 2015
2015-05-27 21:43:05| Logistics - Topix.net
CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced an upcoming poster presentation regarding its lead drug candidate, aldoxorubicin, at the 2015 American Society of Clinical Oncology Annual Meeting, which is being held May 29 - June 2, 2015 in Chicago. "I am impressed by the excellent long-term cardiac safety profile we're seeing in patients who have undergone treatment with aldoxorubicin across several cancer types," said Sant P. Chawla, M.D., F.R.A.C.P., Principal Investigator and Director of the Sarcoma Oncology Center.
Tags: data
positive
presented
clinical
Leading Cancer Centers To Present Clinical Utility Data for Guardant360A At ASCO
2015-05-27 13:10:29| Logistics - Topix.net
This toolset includes: Tumor Response Map: A powerful new visual language of tumor genomics, helping to unify the representation of tumor genomics, heterogeneity and clinical response over time. Enhanced Guardant360 Report: By using the Tumor Response Map and the alteration-specific trend line, the report offers a visual representation of changes and trends in patients' sequential tests, allowing them to quickly see a summary of all detected somatic cfDNA alterations and their quantitative burden, along with available therapeutics and clinical trials.
Tags: data
present
leading
cancer
Next Week In Biotech: Salix/Valeant PDUFA, ASCO, Brain Tumor Summit
2015-05-23 07:25:35| Logistics - Topix.net
Investors in the biotech/healthcare space should be on the lookout for some activity next week even as the earnings doldrums persist. A thin pile of financial updates will be made up for with an expected regulatory action around Salix's - now Valeant's - Xifaxan.
What You Need To Know In Biotech: An ASCO Disappointment, Big Money In Brains And A New CF Drug
2015-05-17 11:51:48| Biotech - Topix.net
Luke Timmerman is a journalist specializing in biotechnology. He is the founder and editor of the Timmerman Report, a subscription publication for biotech insiders.
Eisai to Present New Research on Oncology Products and Pipeline at 51st ASCO Annual Meeting
2015-05-14 14:35:07| Logistics - Topix.net
Highlights Include New Clinical Data on Halaven in Soft Tissue Sarcoma and on Lenvima in Renal Cell Carcinoma TOKYO, May 14, 2015 - - Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and Lenvima with a novel binding mode, "lenvatinib") will be presented during the 51st Annual Meeting of the American Society of Clinical Oncology , taking place in Chicago, the United States, from May 29 to June 2, 2015.
Tags: products
research
present
meeting
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »